Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-03-31
1997-07-22
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
A61K 31425
Patent
active
056504217
ABSTRACT:
A pharmaceutical composition comprising a solution having an effective amount of famotidine, the solution having a pH in the range of about 4.5 to about 8.0, and a shelf life greater than 30 days.
REFERENCES:
patent: 4283408 (1981-08-01), Hirata et al.
patent: 4585790 (1986-04-01), Padfield et al.
patent: 5304571 (1994-04-01), Johnson et al.
patent: 5364616 (1994-11-01), Singer et al.
Johnson & Johnson Mid-Year Report 1995, Cover and p. 11.
The Merck Index, Merck & Co., Inc., 1989, p. 617.
Johnson Douglas G.
Titus Allan E.
Baxter International Inc.
Buonaiuto Mark
Henley III Raymond
Morneault Monique
LandOfFree
Premixed famotidine formulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Premixed famotidine formulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Premixed famotidine formulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1560219